QuadMedicine
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
QuadMedicine develops microneedle patches, tiny needle arrays embedded in a dissolvable tip that push drugs through the skin without a conventional injection, improving how reliably patients take their medicine.
It targets pharmaceutical companies and other drug developers who commission it to adapt already-approved drugs into this skin-delivery format. Listed on KOSDAQ, Korea's tech and small-cap board, the company operates as a contract development and manufacturing partner, earning milestone fees as client projects advance through research, prototype, and clinical stages.
Summary is AI-generated and may contain errors · figures from DART filings
QuadMedicine in five facts
What does QuadMedicine do?
QuadMedicine develops microneedle patches, tiny needle arrays embedded in a dissolvable tip that push drugs through the skin without a conventional injection, improving how reliably patients take their medicine.
Where is QuadMedicine listed and in which sector?
QuadMedicine (Korean name: 쿼드메디슨) trades under KRX code 464490 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is QuadMedicine?
Its market capitalisation was US$38.2M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were QuadMedicine's latest annual revenue and operating profit?
For fiscal year 2025, QuadMedicine reported revenue of US$8.1M, an operating loss of US$4.8M and a net loss of US$5.2M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 15.0% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Material management matter relevant to investment decisionsSep 14
- [Amended] Report on securities held by executives/major shareholdersAug 31
- Report on securities held by executives/major shareholdersAug 31
- Report on securities held by executives/major shareholdersAug 31
- Supply contract signed
QuadMedicine disclosed a supply contract with Hanlim Pharmaceutical Co., Ltd., worth US$4.02M, about 56.1% of its recent annual revenue, running through Mar 2027.
Supply contract · May 15 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
QuadMedicine reported consolidated results for FY2025: revenue of US$7.47M (+16.9% year on year), an operating loss of US$5.26M and a net loss of US$5.63M.
Earnings · Feb 11